Targeted therapies: Congratulations, you are still in the running towards becoming ovarian-next-top treatment. Targeted therapies: Congratulations, you are still in the running towards becoming ovarian-next-top treatment. Nature reviews. Clinical oncology Villanueva MT. PMID: 21912418 Nat Rev Clin Oncol. 2011 Sep 13;8(10):570. doi: 10.1038/nrclinonc.2011.138. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Villanueva MT. Targeted therapies: Congratulations, you are still in the running towards becoming ovarian-next-top treatment. Nat Rev Clin Oncol. 2011;8(10):570doi: 10.1038/nrclinonc.2011.138. APA Villanueva, M. T. (2011). Targeted therapies: Congratulations, you are still in the running towards becoming ovarian-next-top treatment. Nature reviews. Clinical oncology, 8(10), 570. https://doi.org/10.1038/nrclinonc.2011.138 MLA Villanueva, M Teresa. "Targeted therapies: Congratulations, you are still in the running towards becoming ovarian-next-top treatment." Nature reviews. Clinical oncology vol. 8,10 (2011): 570. doi: https://doi.org/10.1038/nrclinonc.2011.138 NLM Villanueva MT. Targeted therapies: Congratulations, you are still in the running towards becoming ovarian-next-top treatment. Nat Rev Clin Oncol. 2011 Sep 13;8(10):570. doi: 10.1038/nrclinonc.2011.138. PMID: 21912418. Copy Download .nbib Format: NLM AMA APA MLA NLM
Gastrointestinal cancer: Mutational signatures reveal distinct subgroups. Gastrointestinal cancer: Mutational signatures reveal distinct subgroups. Nature reviews. Clinical oncology Sidaway P. PMID: 27670231 Nat Rev Clin Oncol. 2016 Nov;13(11):652. doi: 10.1038/nrclinonc.2016.157. Epub 2016 Sep 27. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Sidaway P. Gastrointestinal cancer: Mutational signatures reveal distinct subgroups. Nat Rev Clin Oncol. 2016;13(11):652doi: 10.1038/nrclinonc.2016.157. APA Sidaway, P. (2016). Gastrointestinal cancer: Mutational signatures reveal distinct subgroups. Nature reviews. Clinical oncology, 13(11), 652. https://doi.org/10.1038/nrclinonc.2016.157 MLA Sidaway, Peter. "Gastrointestinal cancer: Mutational signatures reveal distinct subgroups." Nature reviews. Clinical oncology vol. 13,11 (2016): 652. doi: https://doi.org/10.1038/nrclinonc.2016.157 NLM Sidaway P. Gastrointestinal cancer: Mutational signatures reveal distinct subgroups. Nat Rev Clin Oncol. 2016 Nov;13(11):652. doi: 10.1038/nrclinonc.2016.157. Epub 2016 Sep 27. PMID: 27670231. Copy Download .nbib Format: NLM AMA APA MLA NLM
Immunotherapy: Shining light on immune-based mechanisms. Immunotherapy: Shining light on immune-based mechanisms. Nature reviews. Clinical oncology Hutchinson L. PMID: 28925995 Nat Rev Clin Oncol. 2017 Nov;14(11):648-649. doi: 10.1038/nrclinonc.2017.152. Epub 2017 Sep 19. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Hutchinson L. Immunotherapy: Shining light on immune-based mechanisms. Nat Rev Clin Oncol. 2017;14(11):648-649doi: 10.1038/nrclinonc.2017.152. APA Hutchinson, L. (2017). Immunotherapy: Shining light on immune-based mechanisms. Nature reviews. Clinical oncology, 14(11), 648-649. https://doi.org/10.1038/nrclinonc.2017.152 MLA Hutchinson, Lisa. "Immunotherapy: Shining light on immune-based mechanisms." Nature reviews. Clinical oncology vol. 14,11 (2017): 648-649. doi: https://doi.org/10.1038/nrclinonc.2017.152 NLM Hutchinson L. Immunotherapy: Shining light on immune-based mechanisms. Nat Rev Clin Oncol. 2017 Nov;14(11):648-649. doi: 10.1038/nrclinonc.2017.152. Epub 2017 Sep 19. PMID: 28925995. Copy Download .nbib Format: NLM AMA APA MLA NLM
Haematological cancer: Targeted agents: efficacy RESONATEs better with fine tuning. Haematological cancer: Targeted agents: efficacy RESONATEs better with fine tuning. Nature reviews. Clinical oncology Romero D. PMID: 26718104 Nat Rev Clin Oncol. 2016 Feb;13(2):63. doi: 10.1038/nrclinonc.2015.233. Epub 2015 Dec 31. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Romero D. Haematological cancer: Targeted agents: efficacy RESONATEs better with fine tuning. Nat Rev Clin Oncol. 2015;13(2):63doi: 10.1038/nrclinonc.2015.233. APA Romero, D. (2016). Haematological cancer: Targeted agents: efficacy RESONATEs better with fine tuning. Nature reviews. Clinical oncology, 13(2), 63. https://doi.org/10.1038/nrclinonc.2015.233 MLA Romero, Diana. "Haematological cancer: Targeted agents: efficacy RESONATEs better with fine tuning." Nature reviews. Clinical oncology vol. 13,2 (2016): 63. doi: https://doi.org/10.1038/nrclinonc.2015.233 NLM Romero D. Haematological cancer: Targeted agents: efficacy RESONATEs better with fine tuning. Nat Rev Clin Oncol. 2016 Feb;13(2):63. doi: 10.1038/nrclinonc.2015.233. Epub 2015 Dec 31. PMID: 26718104. Copy Download .nbib Format: NLM AMA APA MLA NLM
Breast cancer: Microenvironment mediates differential resistance. Breast cancer: Microenvironment mediates differential resistance. Nature reviews. Clinical oncology Sidaway P. PMID: 28607519 Nat Rev Clin Oncol. 2017 Aug;14(8):458. doi: 10.1038/nrclinonc.2017.89. Epub 2017 Jun 13. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Sidaway P. Breast cancer: Microenvironment mediates differential resistance. Nat Rev Clin Oncol. 2017;14(8):458doi: 10.1038/nrclinonc.2017.89. APA Sidaway, P. (2017). Breast cancer: Microenvironment mediates differential resistance. Nature reviews. Clinical oncology, 14(8), 458. https://doi.org/10.1038/nrclinonc.2017.89 MLA Sidaway, Peter. "Breast cancer: Microenvironment mediates differential resistance." Nature reviews. Clinical oncology vol. 14,8 (2017): 458. doi: https://doi.org/10.1038/nrclinonc.2017.89 NLM Sidaway P. Breast cancer: Microenvironment mediates differential resistance. Nat Rev Clin Oncol. 2017 Aug;14(8):458. doi: 10.1038/nrclinonc.2017.89. Epub 2017 Jun 13. PMID: 28607519. Copy Download .nbib Format: NLM AMA APA MLA NLM
Breast Cancer: Abemaciclib effective in combination with aromatase inhibition. Breast Cancer: Abemaciclib effective in combination with aromatase inhibition. Nature reviews. Clinical oncology Sidaway P. PMID: 29039423 Nat Rev Clin Oncol. 2017 Dec;14(12):714. doi: 10.1038/nrclinonc.2017.169. Epub 2017 Oct 17. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Sidaway P. Breast Cancer: Abemaciclib effective in combination with aromatase inhibition. Nat Rev Clin Oncol. 2017;14(12):714doi: 10.1038/nrclinonc.2017.169. APA Sidaway, P. (2017). Breast Cancer: Abemaciclib effective in combination with aromatase inhibition. Nature reviews. Clinical oncology, 14(12), 714. https://doi.org/10.1038/nrclinonc.2017.169 MLA Sidaway, Peter. "Breast Cancer: Abemaciclib effective in combination with aromatase inhibition." Nature reviews. Clinical oncology vol. 14,12 (2017): 714. doi: https://doi.org/10.1038/nrclinonc.2017.169 NLM Sidaway P. Breast Cancer: Abemaciclib effective in combination with aromatase inhibition. Nat Rev Clin Oncol. 2017 Dec;14(12):714. doi: 10.1038/nrclinonc.2017.169. Epub 2017 Oct 17. PMID: 29039423. Copy Download .nbib Format: NLM AMA APA MLA NLM
Haematological cancer: Rituximab enhances responses to lenalidomide. Haematological cancer: Rituximab enhances responses to lenalidomide. Nature reviews. Clinical oncology Sidaway P. PMID: 27958295 Nat Rev Clin Oncol. 2017 Feb;14(2):70. doi: 10.1038/nrclinonc.2016.210. Epub 2016 Dec 13. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Sidaway P. Haematological cancer: Rituximab enhances responses to lenalidomide. Nat Rev Clin Oncol. 2016;14(2):70doi: 10.1038/nrclinonc.2016.210. APA Sidaway, P. (2017). Haematological cancer: Rituximab enhances responses to lenalidomide. Nature reviews. Clinical oncology, 14(2), 70. https://doi.org/10.1038/nrclinonc.2016.210 MLA Sidaway, Peter. "Haematological cancer: Rituximab enhances responses to lenalidomide." Nature reviews. Clinical oncology vol. 14,2 (2017): 70. doi: https://doi.org/10.1038/nrclinonc.2016.210 NLM Sidaway P. Haematological cancer: Rituximab enhances responses to lenalidomide. Nat Rev Clin Oncol. 2017 Feb;14(2):70. doi: 10.1038/nrclinonc.2016.210. Epub 2016 Dec 13. PMID: 27958295. Copy Download .nbib Format: NLM AMA APA MLA NLM
Haematological cancer: Pembrolizumab is effective in multiple myeloma. Haematological cancer: Pembrolizumab is effective in multiple myeloma. Nature reviews. Clinical oncology Sidaway P. PMID: 28534530 Nat Rev Clin Oncol. 2017 Jul;14(7):393. doi: 10.1038/nrclinonc.2017.76. Epub 2017 May 23. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Sidaway P. Haematological cancer: Pembrolizumab is effective in multiple myeloma. Nat Rev Clin Oncol. 2017;14(7):393doi: 10.1038/nrclinonc.2017.76. APA Sidaway, P. (2017). Haematological cancer: Pembrolizumab is effective in multiple myeloma. Nature reviews. Clinical oncology, 14(7), 393. https://doi.org/10.1038/nrclinonc.2017.76 MLA Sidaway, Peter. "Haematological cancer: Pembrolizumab is effective in multiple myeloma." Nature reviews. Clinical oncology vol. 14,7 (2017): 393. doi: https://doi.org/10.1038/nrclinonc.2017.76 NLM Sidaway P. Haematological cancer: Pembrolizumab is effective in multiple myeloma. Nat Rev Clin Oncol. 2017 Jul;14(7):393. doi: 10.1038/nrclinonc.2017.76. Epub 2017 May 23. PMID: 28534530. Copy Download .nbib Format: NLM AMA APA MLA NLM
Genetics: APOBEC conundrum solved. Genetics: APOBEC conundrum solved. Nature reviews. Clinical oncology Hutchinson L. PMID: 27725676 Nat Rev Clin Oncol. 2016 Nov;13(11):651. doi: 10.1038/nrclinonc.2016.165. Epub 2016 Oct 11. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Hutchinson L. Genetics: APOBEC conundrum solved. Nat Rev Clin Oncol. 2016;13(11):651doi: 10.1038/nrclinonc.2016.165. APA Hutchinson, L. (2016). Genetics: APOBEC conundrum solved. Nature reviews. Clinical oncology, 13(11), 651. https://doi.org/10.1038/nrclinonc.2016.165 MLA Hutchinson, Lisa. "Genetics: APOBEC conundrum solved." Nature reviews. Clinical oncology vol. 13,11 (2016): 651. doi: https://doi.org/10.1038/nrclinonc.2016.165 NLM Hutchinson L. Genetics: APOBEC conundrum solved. Nat Rev Clin Oncol. 2016 Nov;13(11):651. doi: 10.1038/nrclinonc.2016.165. Epub 2016 Oct 11. PMID: 27725676. Copy Download .nbib Format: NLM AMA APA MLA NLM
Immunotherapy: Exploiting natural killers in AML. Immunotherapy: Exploiting natural killers in AML. Nature reviews. Clinical oncology Killock D. PMID: 27725681 Nat Rev Clin Oncol. 2016 Nov;13(11):654. doi: 10.1038/nrclinonc.2016.167. Epub 2016 Oct 11. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Killock D. Immunotherapy: Exploiting natural killers in AML. Nat Rev Clin Oncol. 2016;13(11):654doi: 10.1038/nrclinonc.2016.167. APA Killock, D. (2016). Immunotherapy: Exploiting natural killers in AML. Nature reviews. Clinical oncology, 13(11), 654. https://doi.org/10.1038/nrclinonc.2016.167 MLA Killock, David. "Immunotherapy: Exploiting natural killers in AML." Nature reviews. Clinical oncology vol. 13,11 (2016): 654. doi: https://doi.org/10.1038/nrclinonc.2016.167 NLM Killock D. Immunotherapy: Exploiting natural killers in AML. Nat Rev Clin Oncol. 2016 Nov;13(11):654. doi: 10.1038/nrclinonc.2016.167. Epub 2016 Oct 11. PMID: 27725681. Copy Download .nbib Format: NLM AMA APA MLA NLM
Haematological cancer: Genomic disruption of CD7 avoids fractricide. Haematological cancer: Genomic disruption of CD7 avoids fractricide. Nature reviews. Clinical oncology Sidaway P. PMID: 28607513 Nat Rev Clin Oncol. 2017 Aug;14(8):458. doi: 10.1038/nrclinonc.2017.91. Epub 2017 Jun 13. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Sidaway P. Haematological cancer: Genomic disruption of CD7 avoids fractricide. Nat Rev Clin Oncol. 2017;14(8):458doi: 10.1038/nrclinonc.2017.91. APA Sidaway, P. (2017). Haematological cancer: Genomic disruption of CD7 avoids fractricide. Nature reviews. Clinical oncology, 14(8), 458. https://doi.org/10.1038/nrclinonc.2017.91 MLA Sidaway, Peter. "Haematological cancer: Genomic disruption of CD7 avoids fractricide." Nature reviews. Clinical oncology vol. 14,8 (2017): 458. doi: https://doi.org/10.1038/nrclinonc.2017.91 NLM Sidaway P. Haematological cancer: Genomic disruption of CD7 avoids fractricide. Nat Rev Clin Oncol. 2017 Aug;14(8):458. doi: 10.1038/nrclinonc.2017.91. Epub 2017 Jun 13. PMID: 28607513. Copy Download .nbib Format: NLM AMA APA MLA NLM
Targeted therapies: Precision medicine for ATC - BRAF and MEK inhibition shows promise. Targeted therapies: Precision medicine for ATC - BRAF and MEK inhibition shows promise. Nature reviews. Clinical oncology Killock D. PMID: 29149109 Nat Rev Clin Oncol. 2017 Dec;14(12):712-713. doi: 10.1038/nrclinonc.2017.181. Epub 2017 Nov 17. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Killock D. Targeted therapies: Precision medicine for ATC - BRAF and MEK inhibition shows promise. Nat Rev Clin Oncol. 2017;14(12):712-713doi: 10.1038/nrclinonc.2017.181. APA Killock, D. (2017). Targeted therapies: Precision medicine for ATC - BRAF and MEK inhibition shows promise. Nature reviews. Clinical oncology, 14(12), 712-713. https://doi.org/10.1038/nrclinonc.2017.181 MLA Killock, David. "Targeted therapies: Precision medicine for ATC - BRAF and MEK inhibition shows promise." Nature reviews. Clinical oncology vol. 14,12 (2017): 712-713. doi: https://doi.org/10.1038/nrclinonc.2017.181 NLM Killock D. Targeted therapies: Precision medicine for ATC - BRAF and MEK inhibition shows promise. Nat Rev Clin Oncol. 2017 Dec;14(12):712-713. doi: 10.1038/nrclinonc.2017.181. Epub 2017 Nov 17. PMID: 29149109. Copy Download .nbib Format: NLM AMA APA MLA NLM
